Rosemary Dziak

Dr. Rosemary Dziak


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in Journal of Periodontology
Verified
Journal Article
Closed access
PDF file
JBJeremy Bateman
Jeremy Bateman
GIGiuseppe Intini
Giuseppe Intini
JMJoseph Margarone
Joseph Margarone
SGSamuel Goodloe
Samuel Goodloe
PBPeter Bush
Peter Bush
RDRosemary Dziak
Rosemary Dziak
Background: The use of alloplastic matrices that mimic the mineral phase of bone has become a viable alternative to current mainstream therapies in dentistry such as allografts and autogenous grafts. Because alloplastic bone substitutes generally have relatively poor osteogenic properties, analyzing their potential as vehicles to deliver growth factors is an important step in assessing methods to enhance their clinical efficacy. The aim of these studies was to treat beta‐tricalcium phosphate (β‐TCP) and calcium sulfate (CaSO4) with platelet‐derived growth factor (PDGF)‐BB to enhance the osteogenic capabilities of these materials.Methods: In the β‐TCP studies, PDGF‐BB adsorption and release were accomplished using 125I radiolabeled growth factor and non‐radioactive human recombinant PDGF at a ratio of 1:300 M. For the adsorption studies, the radiolabeled PDGF‐BB/ non‐radioactive PDGF solutions with resultant PDGF concentrations of 10−7 and 10−8 M were incubated with β‐TCP from 1 to 120 minutes, and the amount of adsorbed 125I‐PDGF‐BB was measured using a gamma counter. Similar adsorption studies were conducted with a 30‐minute incubation of β‐TCP with various PDGF concentrations. In vitro release studies were conducted with β‐TCP to which radiolabeled PDGF had been adsorbed as above. Release studies were also conducted with CaSO4 that was hydrated with the radioactive PDGF solution described above for the TCP studies. In vivo PDGF‐BB release from β‐TCP and CaSO4 was evaluated in a mouse model, where the radioactive PDGF/non‐radioactive PDGF‐BB treated β‐TCP or CaSO4 sample was inserted subcutaneously and later removed for radioactive measurement. Proliferation of human osteoblastic cells in the presence of PDGF‐ treated β‐TCP or CaSO4 was assessed by 3H thymidine incorporation.Results: The absorption studies revealed that PDGF‐BB was absorbed in a concentration and time‐dependent manner to β‐TCP. In the in vitro release studies, ∼45% of the adsorbed PDGF‐BB was released after 10 days. In vivo release from both materials occurred faster than in vitro release. Osteoblastic cells incubated with PDGF‐BB‐treated matrices showed significantly (P <0.05, ANOVA) greater proliferation than with control matrices alone.Conclusion: These experiments demonstrate the feasibility of using PDGF‐BB in combination with alloplastic materials such as β‐TCP or CaSO4 to serve as more effective bone graft materials with enhanced osteogenic properties.

1 March 2003 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
RDRosemary Dziak
Rosemary Dziak
BYB.M Yang
B.M Yang
BLB.W Leung
B.W Leung
SLS Li
S Li
NMN Marzec
N Marzec
LBL Bobek
L Bobek

29 June 2016 in Tissue Engineering Part A
Verified
Journal Article
Closed access
XYXue Yuan
Xue Yuan
RSRandall J. Smith
Randall J. Smith
HGHuiyan Guan
Huiyan Guan
CICiprian N. Ionita
Ciprian N. Ionita
PKParag Khobragade
Parag Khobragade
SYShuying Yang
Shuying Yang
Bone is a highly vascularized tissue and efficient bone regeneration requires neovascularization, especially for critical-sized bone defects. We developed a novel hybrid biomaterial comprising nanocalcium sulfate (nCS) and fibrin hydrogel to deliver mesenchymal stem cells (MSCs) and angiogenic factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor 9 (FGF9), to promote neovascularization and bone formation. MSC and growth factor(s)-loaded scaffolds were implanted subcutaneously into mice to examine their angiogenic and osteogenic potential. Micro CT, alkaline phosphatase activity assay, and histological analysis were used to evaluate bone formation, while immunohistochemistry was employed to assess neovessel formation. The presence of fibrin preserved the nCS scaffold structure and promoted de novo bone formation. In addition, the presence of bone morphogenic protein 2-expressing MSC in nCS and fibrin hydrogels improved bone regeneration significantly. While FGF9 alone had no significant effect, the combination FGF9 and VEGF conjugated in fibrin enhanced neovascularization and bone formation more than 4-fold compared to nCS with MSC. Overall, our results suggested that the combination of nCS (to support bone formation) with a fibrin-based VEGF/FGF9 release system (support vascular formation) is an innovative and effective strategy that significantly enhanced ectopic bone formation in vivo .

1 September 2017 in Dental Materials
Verified
Journal Article
Closed access
AAAdi Alghanem
Adi Alghanem
GFGabriela Fernandes
Gabriela Fernandes
MVMichelle Visser
Michelle Visser
RDRosemary Dziak
Rosemary Dziak
WRWalter G. Renné
Walter G. Renné
CSCamila Sabatini
Camila Sabatini

1 January 2017 in Cogent Biology
Verified
Journal Article
Open access
MFmaria gabriela fernandes
maria gabriela fernandes
ABAndrew W. Barone
Andrew W. Barone
RDRosemary Dziak
Rosemary Dziak
Ascorbic acid (Vitamin C) has long been known for its anti-cancer properties and in the present study the effects of ascorbic acid (AsA) on osteogenic differentiation, apoptosis, and signaling pathways of the human G29 osteosarcoma cell line were studied. The expression of Runt-related transcription factor-2 (RUNX2) and osteocalcin genes were evaluated by real-time polymerase chain reaction (PCR). Osteoblastic maturation was assessed with alkaline phosphatase activity and mineralization with alizarin red deposition, and apoptosis with a caspase-2 apoptotic assay as well as the cell viability via the cytotoxicity assay. The possible role of the MAP kinase pathway (p44/42, p38, and p-JNK signaling pathway) was also studied. Our results showed that RUNX2 and osteocalcin gene expression, mineralization, cell viability, and metabolic activity levels were increased in cells treated with low concentrations of AsA with respect to untreated cells. At higher concentrations, AsA resulted in decreases in these parameters and induced apoptosis of the G292 osteosarcoma cells via downregulation of the MAPK pathway. The findings presented here support the ability of AsA to modulate the viability and differentiation of the G292 type of bone cancer cell with increases or decreases depending on the AsA concentration suggesting a need for further evaluation of the possible use of this vitamin in the regulation of bone cell cancer growth.

5 September 2013 in Immunological Investigations
Verified
Journal Article
Closed access
RDRosemary Dziak
Rosemary Dziak
The bioactive lipid molecules, sphingosine-1-phosphate (S1P) and lysophosphatidic acid LPA) have recently emerged as potentially highly significant physiological and pathophysiological regulators of bone cell biology. Since compromised signaling by these bioactive lipids has been implicated in the etiology of disorders such as inflammatory and autoimmune diseases, their role in bone biology can be a key influence in the coordination of the events underlying osteoimmunology. Both S1P and LPA have been shown to have receptor-mediated effects on osteoblastic cell proliferation and differentiation critical to bone formation and on osteoclastic cell action and regulation of bone resorption. This review of the recent studies on these processes provides insight into the potential role of S1P and LPA as autocrine and paracrine mediators of bone remodeling and their potential interaction with immune cells that have emerged as important players in skeletal biology.